Thyroid Eye Disease (TED) Clinical Trials
Kriya Therapeutics is a biopharmaceutical company developing gene therapies to address common chronic diseases of high unmet need. Our mission is to make gene therapies accessible – not just for the few – but for the many.
Kriya is developing KRIYA-586, an investigational one-time gene therapy for thyroid eye disease (TED) designed to be delivered by an in-office peribulbar injection. KRIYA-586 is an adeno-associated virus (AAV) gene therapy engineered to express an antibody that inhibits Insulin-Like Growth Factor 1 Receptor (IGF1R).
The RECLAIM Study is an adaptive Phase 1/2 multicenter study evaluating the safety, tolerability, pharmacokinetics, and efficacy of KRIYA-586 in patients with moderate to severe TED.
Thyroid Eye Disease Clinical Trial
https://clinicaltrials.gov/study/NCT07404111
KRIYA-586 is an investigational therapy and has not been approved as safe or effective by the FDA or any other regulatory health authority.
VitaliThy
Official Study Name:
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease (VitaliThy)
ClinicalTrials.gov ID: NCT07596849
• Other study numbers: ARGX-113-25-GRD-3001; ARGX-113-25-GRD-3002
• 2025-524223-42-00 ( EU Trial (CTIS) Number )
• 2025-523333-26-00 ( EU Trial (CTIS) Number )
Mode of delivery: Subcutaneous injection via Prefilled Syringe (PFS)
Primary Outcome Measure:
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Amgen is conducting a Clinical Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
Thyroid Eye Disease Clinical Trial
https://clinicaltrials.gov/study/NCT06248619
Brief Summary
The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period.
Detailed Description
The main objective of the study is to evaluate the effect of teprotumumab subcutaneous administration versus placebo on the proptosis responder rate (ie, the percentage of participants with a ≥ 2-mm reduction from Baseline in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye) at Week 24.
IN THE NEWS
THOUSAND OAKS, Calif., April 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced positive topline results from a Phase 3 trial of TEPEZZA (teprotumumab-trbw) administered by subcutaneous injection via an on-body injector (OBI) in participants with moderate-to-severe active Thyroid Eye Disease (TED). TEPEZZA OBI provides comparable efficacy to, and builds upon the success of, intravenous (IV) TEPEZZA, the first and only medicine approved for the treatment of TED, which has now treated more than 25,000 patients worldwide.
Tourmaline Bio, Inc. is conducting a clinical trial for thyroid eye disease.
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease (spiriTED)
Thyroid Eye Disease Clinical Trial
https://clinicaltrials.gov/study/NCT06088979
Brief Summary
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Official Title
A Multicenter Phase 2b Randomized, Double-Masked, Placebo-Controlled Dose-Ranging Study of TOUR006 in Participants With Thyroid Eye Disease
Sling Therapeutics’ is investigating a convenient oral small molecule linsitinib for thyroid eye disease (TED).
Linsitinib works by inhibiting the validated IGF-1R target.
Note: Linsitinib is not approved as a marketed product at this time. Clinical trials are required by the FDA to demonstrate the safety and efficacy of a potential medication before general availability.
GRAVES’ DISEASE CLINICAL TRIAL
Immunovant is also conducting a clinical trial for Graves’ Disease. A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves’ Disease.
Brief Summary
This is a study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves’ disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
The primary objective of this study is to evaluate the efficacy of IMVT-1402 versus placebo as assessed by T3 (total triiodothyronine [T3] or free triiodothyronine [FT3]), free thyroxine (FT4), thyroid-stimulating hormone (TSH), and ATD dose at Week 26.
Graves’ Disease Clinical Trial
https://clinicaltrials.gov/study/NCT06727604
Viridian is a biotechnology company based in Waltham, Massachusetts focused on discovering and developing potential new medicines for people living with autoimmune and rare diseases.
Leveraging our team’s expertise in antibody discovery, protein engineering, and clinical development, Viridian is studying multiple potential new treatment options in clinical trials for people living with thyroid eye disease (TED). All of Viridian’s TED clinical trials are fully enrolled, therefore no longer seeking additional participants. For more information on these clinical trials, please visit https://clinicaltrials.gov/search?lead=Viridian or speak with a healthcare provider.
We’re Genentech. Our love of science compels us to explore new avenues of research and untapped technological possibilities in pursuit of solutions that reduce the burden of complex health challenges on patients.
As biotech’s original changemakers, we deliver life-changing breakthroughs – from creating the next generation of therapies, to accelerating the drug discovery process – improving healthcare access and outcomes for all patients.
We are inclusive, passionate, vibrant and courageous, constantly working towards a shared goal of a healthier future.
Genentech is committed to improving health outcomes within the communities we serve. We do this by supporting and promoting organizations and initiatives that offer new opportunities for care and by improving access to health services and information.
On Our Watch List
Alumis is investigating a medication for thyroid eye disease. Lonigutamab, a next-generation anti-IGF-1R, is being explored as a potential TED treatment, offering a convenient subcutaneous route of administration and safety benefit while retaining the clinically validated efficacy of an anti-IGF-1R.
More information:
https://www.alumis.com/pipeline/lonigutamab/
About TED Community Organization
This thyroid eye disease and Graves’ disease patient advocacy group frequently maintains an updated, accessible list of open TED clinical program.